Terns Pharmaceuticals Faces Major Shift as Merck Announces $6.7 B Acquisition

The biopharmaceutical landscape is poised for a significant realignment following Merck & Co., Inc.’s definitive agreement to acquire Terns Pharmaceuticals, Inc. for $6.7 billion—a transaction that will shape the oncology and liver‑disease markets for years to come.

Transaction Overview

  • Deal Value: $6.7 billion, translating to $53.00 per share for Terns shareholders.
  • Market Impact: Terns’ shares rose ≈5 % in early trading on March 25, 2026, as the market reacted to the announcement.
  • Strategic Fit: The acquisition expands Merck’s cancer portfolio, particularly in the hematology sector, and brings a promising oral‑molecule pipeline into Merck’s development ecosystem.

Merck’s intent is clear: to bolster its oncology offerings ahead of the Keytruda competitive landscape and to secure access to Terns’ late‑stage candidate for chronic myeloid leukemia (CML), a disease that represents a significant unmet need.

Terns’ Position in the Market

  • Specialization: The company focuses on molecularly‑targeted oral drugs for liver disease and cancer.
  • Financial Snapshot (as of March 23, 2026):
  • Close Price: $50
  • 52‑Week High: $50.89
  • 52‑Week Low: $1.865
  • Market Capitalization: $5.4 billion
  • Price‑to‑Earnings Ratio: –48.12 (negative due to ongoing R&D costs and pre‑revenue status).

Terns operates from Foster City, California, and serves a global customer base. Its pipeline has attracted attention from major investors, but the company remains in a high‑growth, high‑risk stage typical of clinical‑stage oncology firms.

Market Reactions and Analyst Commentary

  • Downgrade by HC Wainwright & Co.: Prior to the Merck announcement, HC Wainwright had reduced its recommendation for Terns, citing concerns over valuation and execution risk.
  • Class‑Action Alert: A shareholder alert surfaced, highlighting potential regulatory scrutiny and legal ramifications surrounding the merger, underscoring the complexity of M&A activity in the biopharma sector.
  • Positive Momentum: Despite the downgrade and legal alert, the market’s immediate response was bullish, with a 5% uptick in share price—reflecting investor enthusiasm for the new partnership and potential upside from the integration.

Strategic Implications for Merck

Merck’s acquisition strategy appears to target high‑impact, high‑risk candidates that can accelerate its pipeline without the lead‑time of developing from scratch. By adding Terns’ orally available CML agent, Merck:

  • Diversifies its oncology portfolio beyond its flagship immuno‑checkpoint inhibitor, Keytruda.
  • Positions itself advantageously against emerging competitors in the CML space.
  • Secures access to innovative drug delivery platforms that could be leveraged across other therapeutic areas.

Outlook for Terns’ Stakeholders

For Terns shareholders, the $53.00 per share offer represents a premium over the recent trading levels, potentially delivering a substantial return given the company’s valuation constraints. The deal also promises:

  • Liquidity for existing investors.
  • Expanded resources for accelerated clinical development of its pipeline.
  • Integration into a global corporate structure, providing greater regulatory and commercial reach.

Conclusion

Merck’s $6.7 billion purchase of Terns Pharmaceuticals marks a pivotal moment for both companies. It signals Merck’s intent to strengthen its oncology and liver‑disease offerings, while providing Terns with the financial and operational support needed to advance its promising oral‑molecule drugs. As the biopharmaceutical arena continues to evolve, such high‑profile acquisitions underscore the importance of strategic alignment, robust pipelines, and the willingness to navigate complex regulatory and legal landscapes.